文献速递脊柱外科

替尔泊肽与其他GLP-1受体激动剂腰椎融合术后远期机械并发症比较

Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists.
PubMed 文献 · Spine (Phila Pa 1976) · 2026-06-18

该回顾性队列研究利用TriNetX数据库比较替尔泊肽与非替尔泊肽GLP-1受体激动剂患者腰椎融合术后的结局。经倾向评分匹配后,两组90天并发症相似;但替尔泊肽组在2年和3年时的假关节形成及内固定失败率显著更低,翻修率无差异。

要点

  • 替尔泊肽组90天医疗并发症、住院及急诊就诊与非替尔泊肽GLP-1 RA组相似。
  • 术后2年替尔泊肽组假关节形成率3.1% vs 5.5%,内固定失败率1.5% vs 3.5%,均显著更低。
  • 术后3年替尔泊肽组假关节形成率3.1% vs 6.0%,内固定失败率1.6% vs 3.7%,仍显著更低。

核心结论

  • 替尔泊肽与非替尔泊肽GLP-1受体激动剂相比,腰椎融合术后短期安全性相当,且远期机械并发症发生率更低。

研究设计与样本

  • 回顾性队列研究,使用TriNetX全球协作网络纳入接受腰椎融合术的成年患者。
  • 暴露定义为术前一年内处方替尔泊肽或非替尔泊肽GLP-1受体激动剂,并进行1:1倾向评分匹配。

主要发现

  • 匹配后两组90天医疗并发症、住院和急诊就诊无显著差异(P>0.05)。
  • 术后1年两组假关节形成(3.0% vs 3.8%)、内固定失败(1.4% vs 1.7%)和翻修手术(1.3% vs 1.3%)均无显著差异(P>0.05)。
  • 术后2年替尔泊肽组假关节形成(3.1% vs 5.5%,RR 0.56,95%CI 0.35-0.90,P=0.016)和内固定失败(1.5% vs 3.5%,RR 0.42,95%CI 0.22-0.80,P=0.006)显著更低,翻修率无差异。
  • 术后3年替尔泊肽组假关节形成(3.1% vs 6.0%,RR 0.51,95%CI 0.32-0.82,P=0.005)和内固定失败(1.6% vs 3.7%,RR 0.43,95%CI 0.23-0.79,P=0.005)仍显著更低,翻修手术无显著差异。

临床怎么用

  • 对于接受腰椎融合术且需GLP-1受体激动剂治疗的患者,替尔泊肽可能有利于降低远期假关节形成和内固定失败风险。
  • 短期安全性相当,但远期机械并发症差异需在前瞻性研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Retrospective cohort study. OBJECTIVE: To compare short-term outcomes and long-term mechanical complications following lumbar fusion in patients receiving tirzepatide versus non-tirzepatide glucagon-like peptide-1 receptor agonists (GLP-1 RAs). SUMMARY OF BACKGROUND DATA: GLP-1 RAs have demonstrated metabolic and anti-inflammatory effects that may influence postoperative recovery. Tirzepatide, a dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP), has shown greater metabolic efficacy than traditional GLP-1 RAs, though its impact on spinal fusion outcomes remains unclear. METHODS: A retrospective cohort analysis was performed using the TriNetX Global Collaborative Network for adult patients undergoing lumbar fusion. Exposure was defined by tirzepatide or non tirzepatide GLP-1 RAs prescription within one year before surgery. Propensity score matching (1:1) was conducted using demographic and clinical covariates. Ninety-day complications and mechanical outcomes from 1-3 years were evaluated using risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: After matching, ninety-day medical complications, hospitalizations and emergency department visits were similar between groups (P>0.05). At one year, pseudoarthrosis (3.0% vs 3.8%), instrumentation failure (1.4% vs 1.7%), and revision surgery (1.3% vs 1.3%) were comparable between groups (P>0.05). By two years, tirzepatide was associated with significantly lower pseudoarthrosis (3.1% vs 5.5%, RR 0.56, 95% CI 0.35-0.90, P=0.016) and instrumentation failure (1.5% vs 3.5%, RR 0.42, 95% CI 0.22-0.80, P=0.006), with similar revision rates. At three years, pseudoarthrosis (3.1% vs 6.0%, RR 0.51, 95% CI 0.32-0.82, P=0.005) and instrumentation failure (1.6% vs 3.7%, RR 0.43, 95% CI 0.23-0.79, P=0.005) remained significantly lower, while revision surgery remained nonsignificant. CONCLUSION: Tirzepatide was associated with comparable short-term safety and lower rates of long-term mechanical complications after lumbar fusion. These findings suggest differences in mechanical outcomes that emerge over extended follow-up and warrant prospective comparative evaluation.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Wang R, Islam H, Karikaran A, et al. Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists. Spine (Phila Pa 1976). 2026. PMID: 42348793. doi:10.1097/BRS.0000000000005773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。